News

Share

Aa-+

Here is the latest news about the Montreal Heart Institute.

Subscribe to news feed
  • Dr. Jean-Claude Tardif Receives the Prestigious Margolese National Heart Disorders Prize

    September 10, 2021

    The Montreal Heart Institute (MHI) is proud to announce that Dr. Jean-Claude Tardif has been honoured with the 2021 Margolese National Heart Disorders Prize.

    This prestigious distinction is awarded annually to a Canadian physician or scientist who makes outstanding contributions to heart disorders’ treatment, amelioration, or cure.

    Read more

  • Health Canada approval of low-dose colchicine for cardiovascular disease based on the COLCOT study

    August 27, 2021

    MYINFLA™ 0.5 mg has been approved by Health Canada for the reduction of cardiovascular risk in patients with coronary disease. MONTREAL, August 27, 2021 – People with coronary disease now have a new treatment option to reduce the risk of cardiovascular events. Health Canada has issued a Notice of Compliance for the prescription drug MYINFLA™ (colchicine 0.5 mg tablets) based on the results of the Montreal Heart Institute (MHI)’s COLCOT clinical trial.

    Read more

  • Canadian first: The Department of Surgery implants a new biological aortic prosthesis

    June 8, 2021

    The Montreal Heart Institute (MHI) announces that the surgery department has implanted a new biological aortic prosthesis in a patient, a Canadian first. This cutting-edge medical device reduces the time required for surgery and the risk of complications; thus, patients enjoy a better quality of life.

    Read more

  • Results of the COLCORONA study published in The Lancet Respiratory Medicine

    May 27, 2021

    Colchicine could be considered as a treatment for non-hospitalized patients diagnosed with COVID-19 by PCR test and at risk of complications.

    Read more

  • BRAIN-AF Study Receives Canadian Institutes of Health Research Grant

    March 16, 2021


    The Montreal Heart Institute (MHI) announces that the BRAIN-AF study has received a $1.4 million grant from the Canadian Institutes of Health Research. Seeking to better understand the effects of cardiovascular disease on the cognitive decline of the brain, the study will be able to recruit participants remotely thanks to this funding.

    Read more

  • New Clinical Trial on Hesperidin

    February 16, 2021


    A natural product to fight symptoms related to COVID-19

    The Montreal Heart Institute (MHI) is launching a new clinical trial to evaluate the effect of hesperidin on symptoms related to COVID-19. This flavonoid naturally found in citrus fruits has distinct properties that may reduce the entry and replication of the SARS-CoV2 virus in the body along with the modulation of inflammatory mediators, thus potentially reducing symptoms and prevent complications from the disease.

    Read more

  • Caregiver visits suspended at 3rd East and 3rd Center

    January 29, 2021

    Due to an outbreak in the surgical continuum, caregiver visits are suspended indefinitely.

    Caregivers will not be able to come to the surgical intensive care unit (3rd east) and the surgical unit (3rd center) until further notice.

    In exceptional situations or for humanitarian reasons (eg: end of life), a caregiver may be authorized, with the agreement of the care unit.

    Read more

  • Major scientific breakthrough to treat COVID-19

    January 27, 2021

    UPDATE: COLCORONA study manuscript is now available in the public domain.

    READ THE MANUSCRIPT

    On January 22, 2021, the Montreal Heart Institute announced positive results from COLCORONA trial. These results showed that colchicine is the only effective oral medication for treating non-hospitalized patients.

    Read more

  • A new discovery in heart muscle disease

    January 26, 2021

    This medical breakthrough could help prevent the leading cause of sudden death in young people.

    An international team of researchers co-led by Dr. Rafik Tadros, Cardiologist at the Montreal Heart Institute and Assistant Professor at the Université de Montréal, has identified new genetic traits associated with heart muscle disease (cardiomyopathy). This breakthrough, published today in the prestigious scientific journal Nature Genetics, could have a significant impact in the development of drugs against this disease whose mechanisms are still little known.

    Read more

  • Colchicine reduces the risk of COVID-19-related complications

    January 23, 2021

    Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients

    Read more

Pages